ANGPT1 and ovarian cancer: In clinical PhII studies of recurrent ovarian cancer, combination of Ang 1/2 cross-reactive molecule AMG386 and Paclitaxel resulted in prolonged progression free survival in a dose dependent manner (from 4.6 to 7.2 month for 10 mg/kg AMG386 plus paclitaxel) [40].